Review



okt3 mokt3  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC okt3 mokt3
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Okt3 Mokt3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1378 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/okt3 mokt3/product/ATCC
    Average 96 stars, based on 1378 article reviews
    okt3 mokt3 - by Bioz Stars, 2026-02
    96/100 stars

    Images

    1) Product Images from "Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8 + T cell fate to enhance anti-tumor functionality"

    Article Title: Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8 + T cell fate to enhance anti-tumor functionality

    Journal: bioRxiv

    doi: 10.64898/2026.01.21.700812

    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of A375-mOKT3 tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Figure Legend Snippet: CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of A375-mOKT3 tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.

    Techniques Used: CRISPR, Co-Culture Assay, RNA Sequencing, Activity Assay, Quantitative Proteomics



    Similar Products

    96
    ATCC okt3 mokt3
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Okt3 Mokt3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/okt3 mokt3/product/ATCC
    Average 96 stars, based on 1 article reviews
    okt3 mokt3 - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec cd3 antibody, anti-human
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Cd3 Antibody, Anti Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd3 antibody, anti-human/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    cd3 antibody, anti-human - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    ATCC hybridoma cell line okt3
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Hybridoma Cell Line Okt3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hybridoma cell line okt3/product/ATCC
    Average 96 stars, based on 1 article reviews
    hybridoma cell line okt3 - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    96
    ATCC antibody okt3
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Antibody Okt3, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibody okt3/product/ATCC
    Average 96 stars, based on 1 article reviews
    antibody okt3 - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec okt3 anti cd3 antibody
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Okt3 Anti Cd3 Antibody, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/okt3 anti cd3 antibody/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    okt3 anti cd3 antibody - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    96
    Miltenyi Biotec antibodies targeting cd3 okt3
    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of <t>A375-mOKT3</t> tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.
    Antibodies Targeting Cd3 Okt3, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies targeting cd3 okt3/product/Miltenyi Biotec
    Average 96 stars, based on 1 article reviews
    antibodies targeting cd3 okt3 - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    Image Search Results


    CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of A375-mOKT3 tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.

    Journal: bioRxiv

    Article Title: Dual-inactivation of Regnase-1 and SOCS1 rewires exhausted CD8 + T cell fate to enhance anti-tumor functionality

    doi: 10.64898/2026.01.21.700812

    Figure Lengend Snippet: CRISPR/Cas9 engineered TIL (eTIL ® ) were manufactured to inactivate SOCS1 (KSQ-001EX), Regnase-1 (sgRegnase-1), or both SOCS1 and Regnase-1 (KSQ-004EX) with non-electroporated controls used as a benchmark (No EP). (A) Percent killing of A375-mOKT3 tumor spheroids by indicated eTIL. (B) Production of IFNγ from during eTIL co-culture with A375-mOKT3 tumor spheroids. (C) Repeat stimulation assay assessing the ability of eTIL manufactured from a treatment-refractory melanoma donor to kill A375-mOKT3 cells following each stimulation over time. (D) eTIL bulk RNA-Seq, with Principle Components (PC) PC1, PC2 and PC3 depicted. No EP contains 30 independent donors; KSQ-001EX contains 26 independent donors; sgRegnase-1 contains 13 independent donors, and KSQ-004EX contains 25 independent donors. (E) Select DEGs between pairwise eTIL comparisons are depicted, with log fold change depicted by heatmap. (F) The number of DEGs between the eTIL comparisons are depicted by Venn diagram. (G) Transcription factor activity analysis from eTIL bulk RNA-Seq (H) Heatmap of log fold changes of top DEGs between edited TILs versus their respective controls in both human and mouse. Statistical significance between treatment groups was determined using a two-way ANOVA in with ns = no significance, * = p value < 0.05, ** = p value < 0.01, and *** = p value < 0.001. For and , the * in the heatmap represent the adj-p value (Benjamini Hochberg) for pairwise differential expression analysis with DESeq2 where *** = adj-p value < 0.001; ** = 0.001- 0.01; * = 0.01-0.05 and ‘.’ = 0.05-0.1. For , the *s represent adj-p values (Benjamini Hochberg) for transcription factor activity analysis. is representative of n=16 independent donors, is representative of n=7 independent donors. See also Figure S10.

    Article Snippet: The A375 human melanoma cell line was obtained from ATCC and engineered to express either a low-affinity or high-affinity membrane associated anti-CD3 binding domain from clone OKT3 (mOKT3) together with RFP as previously described (Schlabach et al. 2023), with the low-affinity A375-mOKT line used for in vitro spheroid cytotoxicity and IFN- release assays, and the high-affinity A375-mOKT3 line used for the chronic stimulation assay[ ].

    Techniques: CRISPR, Co-Culture Assay, RNA Sequencing, Activity Assay, Quantitative Proteomics